These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17080185)

  • 1. A man who has made his Marks on science.
    Honey K; Marks PA
    J Clin Invest; 2006 Nov; 116(11):2833. PubMed ID: 17080185
    [No Abstract]   [Full Text] [Related]  

  • 2. Histone deacetylase inhibitors in cancer therapy.
    Fouladi M
    Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
    [No Abstract]   [Full Text] [Related]  

  • 3. Restrospective on the last quarter-century in medical oncology.
    Davidson N
    Oncology (Williston Park); 2011 Apr; 25(5):396. PubMed ID: 21710831
    [No Abstract]   [Full Text] [Related]  

  • 4. [[Inhibitors of histone deacetylase as new agents for prevention and treatment of cancer] ].
    Jung M
    Pharm Unserer Zeit; 2000 Nov; 29(6):385-8. PubMed ID: 11199916
    [No Abstract]   [Full Text] [Related]  

  • 5. Epigenetic therapies reach main street.
    Bates SE
    Clin Cancer Res; 2009 Jun; 15(12):3917. PubMed ID: 19528089
    [No Abstract]   [Full Text] [Related]  

  • 6. The potential of histone deacetylase inhibitors in lung cancer.
    Aparicio A
    Clin Lung Cancer; 2006 Mar; 7(5):309-12. PubMed ID: 16640801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticancer activities of histone deacetylase inhibitors.
    Bolden JE; Peart MJ; Johnstone RW
    Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors.
    Kelly WK
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):722-3. PubMed ID: 16163258
    [No Abstract]   [Full Text] [Related]  

  • 9. Histone deacetylase inhibitors: overview and perspectives.
    Dokmanovic M; Clarke C; Marks PA
    Mol Cancer Res; 2007 Oct; 5(10):981-9. PubMed ID: 17951399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted histone deacetylase inhibition for cancer prevention and therapy.
    Palmieri C; Coombes RC; Vigushin DM
    Prog Drug Res; 2005; 63():147-81. PubMed ID: 16265880
    [No Abstract]   [Full Text] [Related]  

  • 11. Takashi Tsuruo.
    Sugimura T
    Mol Cancer Ther; 2009 May; 8(5):989-90. PubMed ID: 19383848
    [No Abstract]   [Full Text] [Related]  

  • 12. [Thirty four years of reports from the war against cancer].
    Thomsen ML
    Ugeskr Laeger; 2005 Dec; 167(50):4746-7. PubMed ID: 16393535
    [No Abstract]   [Full Text] [Related]  

  • 13. HDAC inhibitors: a potential new category of anti-tumor agents.
    Pan LN; Lu J; Huang B
    Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy.
    Piekarz RL; Sackett DL; Bates SE
    Cancer J; 2007; 13(1):30-9. PubMed ID: 17464244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer survivors: a look backward and forward.
    Ganz PA
    J Oncol Pract; 2014 Sep; 10(5):289-93. PubMed ID: 25118209
    [No Abstract]   [Full Text] [Related]  

  • 16. HDAC inhibitors for the treatment of cancer.
    Secrist JP; Zhou X; Richon VM
    Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
    Epping MT; Bernards R
    Int J Biochem Cell Biol; 2009 Jan; 41(1):16-20. PubMed ID: 18765293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Development of histone deacetylase inhibitors Potent active ingredients especially in cancer].
    Heinke R; Sippl W
    Pharm Unserer Zeit; 2010 May; 39(3):183-9. PubMed ID: 20425772
    [No Abstract]   [Full Text] [Related]  

  • 19. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
    Yoshida M; Shimazu T; Matsuyama A
    Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Michael Lazarevich Gershanovich--one of the founders of cancer chemotherapy in Russia].
    Semiglazova TIu; Filatova LV; Stukov AN
    Vopr Onkol; 2014; 60(4):522-4. PubMed ID: 25552077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.